Dannis Gilbert Van Vuurden

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3048898/publications.pdf

Version: 2024-02-01

60 papers 3,658 citations

218677 26 h-index 55 g-index

63 all docs

63
docs citations

63 times ranked

5470 citing authors

#	Article	IF	CITATIONS
1	Dynamic generation of access control policies from social policies. Procedia Computer Science, 2022, 198, 140-147.	2.0	1
2	Imaged-guided focused ultrasound in combination with various formulations of doxorubicin for the treatment of diffuse intrinsic pontine glioma. Translational Medicine Communications, 2022, 7, .	1.4	8
3	DIPG-24. Neurological symptom improvement after re-irradiation in patients with diffuse intrinsic pontine glioma (DIPG): A retrospective analysis of the SIOP-E-HGG/DIPG project Neuro-Oncology, 2022, 24, i23-i23.	1.2	0
4	High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction. Journal of Clinical Oncology, 2021, 39, 1264-1273.	1.6	10
5	Complementary and alternative medicine in children with diffuse intrinsic pontine glioma—A SIOPE DIPG Network and Registry study. Pediatric Blood and Cancer, 2021, 68, e29061.	1.5	4
6	A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2021, 153, 263-271.	2.9	15
7	Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies. Journal of Personalized Medicine, 2021, 11, 869.	2.5	11
8	Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors. Neuro-Oncology Advances, 2021, 3, vdab113.	0.7	2
9	Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors. CNS Drugs, 2020, 34, 1121-1131.	5.9	73
10	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2020, 26, 3319-3332.	7.0	44
11	A High-Throughput Image-Guided Stereotactic Neuronavigation and Focused Ultrasound System for Blood-Brain Barrier Opening in Rodents. Journal of Visualized Experiments, 2020, , .	0.3	1
12	PATH-04. THE BLOOD-BRAIN BARRIER IN DIFFUSE MIDLINE GLIOMA AND ITS IMPLICATIONS FOR DRUG DELIVERY. Neuro-Oncology, 2020, 22, ii164-ii164.	1.2	0
13	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	2.9	36
14	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. Journal of Nuclear Medicine, 2018, 59, 612-615.	5.0	24
15	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology, 2018, 20, 123-131.	1.2	184
16	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250
17	Convection-enhanced delivery: chemosurgery in diffuse intrinsic pontine glioma. Lancet Oncology, The, 2018, 19, 1001-1003.	10.7	2
18	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2018, 24, 5645-5657.	7.0	30

#	Article	IF	CITATIONS
19	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. Lancet Oncology, The, 2018, 19, e419-e428.	10.7	16
20	Declining free thyroxine levels over time in irradiated childhood brain tumor survivors. Endocrine Connections, 2018, 7, 1322-1332.	1.9	2
21	Timed performance weaknesses on computerized tasks in pediatric brain tumor survivors: A comparison with sibling controls. Child Neuropsychology, 2017, 23, 208-227.	1.3	11
22	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	2.9	42
23	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	2.9	27
24	Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. European Journal of Cancer, 2017, 73, 38-47.	2.8	101
25	External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. Journal of Neuro-Oncology, 2017, 134, 231-240.	2.9	21
26	Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Journal of Neurosurgery: Pediatrics, 2017, 19, 518-530.	1.3	23
27	An 8-Year-Old Girl with Ocular Swelling. Journal of Pediatrics, 2017, 181, 324-324.e1.	1.8	O
28	Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. Experimental Cell Research, 2017, 360, 397-403.	2.6	26
29	A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2017, 135, 307-315.	2.9	25
30	Molecular Drug Imaging: ⁸⁹ Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. Journal of Nuclear Medicine, 2017, 58, 711-716.	5.0	69
31	Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates. Frontiers in Oncology, 2017, 7, 254.	2.8	25
32	DIPG-15. EFFECTIVE PRECLINICAL TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA BY MELK INHIBITION. Neuro-Oncology, 2017, 19, iv7-iv8.	1.2	О
33	Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. Oncotarget, 2017, 8, 60447-60452.	1.8	20
34	Highlights of Children with Cancer UK's Workshop on Drug Delivery in Paediatric Brain Tumours. Ecancermedicalscience, 2016, 10, 630.	1.1	2
35	Commentary on "Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypesâ€. Acta Neuropathologica, 2016, 131, 793-794.	7.7	4
36	State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. Journal of Neuro-Oncology, 2016, 128, 387-394.	2.9	18

#	Article	IF	CITATIONS
37	Prevalence and Risk Factors of Early Endocrine Disorders in Childhood Brain Tumor Survivors: A Nationwide, Multicenter Study. Journal of Clinical Oncology, 2016, 34, 4362-4370.	1.6	75
38	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. Molecular Cancer Therapeutics, 2016, 15, 2166-2174.	4.1	51
39	Neurofeedback ineffective in paediatric brain tumour survivors: Results of a double-blind randomised placebo-controlled trial. European Journal of Cancer, 2016, 64, 62-73.	2.8	17
40	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. Neuro-Oncology, 2016, 18, 582-588.	1.2	25
41	Psychosocial profile of pediatric brain tumor survivors with neurocognitive complaints. Quality of Life Research, 2016, 25, 435-446.	3.1	44
42	BT-02 * FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2015, 17, iii3-iii3.	1.2	2
43	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	30.7	473
44	A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Review of Anticancer Therapy, 2015, 15, 157-164.	2.4	41
45	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro-Oncology, 2015, 17, 160-166.	1.2	124
46	18 F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma. EJNMMI Research, 2014, 4, 8.	2.5	4
47	Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathologica, 2014, 127, 931-933.	7.7	53
48	Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro-Oncology, 2014, 16, 946-959.	1.2	31
49	Human pontine glioma cells can induce murine tumors. Acta Neuropathologica, 2014, 127, 897-909.	7.7	63
50	Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathologica, 2014, 128, 605-607.	7.7	74
51	Convection enhanced delivery of carmustine to the murine brainstem: A feasibility study. Journal of Neuroscience Methods, 2014, 238, 88-94.	2.5	22
52	WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas. Molecular Cancer Therapeutics, 2013, 12, 141-150.	4.1	64
53	Cytotoxicity and Radiosensitization of High Grade Glioma Cells by CI-1033, an Irreversible Pan-Erbb Inhibitor. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	0
54	In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma. PLoS ONE, 2013, 8, e61512.	2.5	108

#	ARTICLE	IF	CITATIONS
55	EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival. Clinical Cancer Research, 2012, 18, 4048-4058.	7.0	76
56	EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro-Oncology, 2012, 14, 1125-1135.	1.2	47
57	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	7.7	863
58	PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget, 2011, 2, 984-996.	1.8	85
59	Attenuated AMPA Receptor Expression Allows Glioblastoma Cell Survival in Glutamate-Rich Environment. PLoS ONE, 2009, 4, e5953.	2.5	39
60	Therapeutic total plasma exchange in a child with neuroblastoma-related anti-Hu syndrome. Pediatric Nephrology, 2005, 20, 1655-1656.	1.7	9